Hyloris Developmentsen Sa Cash Flow Conversion Efficiency
Hyloris Developmentsen Sa cash flow conversion efficiency. Based on the latest financial reports, Hyloris Developmentsen Sa (HYL) has a cash flow conversion efficiency ratio of -0.058x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.67 Million ≈ $-1.95 Million USD) by net assets (€28.89 Million ≈ $33.77 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Hyloris Developmentsen Sa (2017–2024)
Cash flow conversion efficiency of Hyloris Developmentsen Sa from 2017 to 2024. This chart illustrates how Hyloris Developmentsen Sa's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Hyloris Developmentsen Sa share price for real-time trading data and today's change.
Hyloris Developmentsen Sa Cash Flow Conversion Ratio Explained
Hyloris Developmentsen Sa cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Hyloris Developmentsen Sa Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hyloris Developmentsen Sa ranked by their cash flow conversion efficiency. Also see Hyloris Developmentsen Sa (HYL) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BINEX Co. Ltd
KQ:053030
|
0.019x |
|
Silk Logistics Holdings Ltd
AU:SLH
|
0.381x |
|
Caisse Regionale De Credit Agricole Mutuel Sud Rhone Alpes
PA:CRSU
|
0.030x |
|
Trio-Tech International
NYSE MKT:TRT
|
0.004x |
|
Mitrabara Adiperdana PT
JK:MBAP
|
-0.004x |
|
LiveWire Group Inc.
NYSE:LVWR
|
-0.459x |
|
Nykode Therapeutics ASA
OL:NYKD
|
-0.079x |
|
Pioneer Floating Rate Trust
NYSE:PHD
|
0.054x |
Annual Cash Flow Conversion Efficiency for Hyloris Developmentsen Sa (2017–2024)
The table below shows the annual cash flow conversion efficiency of Hyloris Developmentsen Sa from 2017 to 2024. Review Hyloris Developmentsen Sa free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €32.14 Million ≈ $37.58 Million |
€-6.70 Million ≈ $-7.84 Million |
-0.209x | +36.39% |
| 2023-12-31 | €39.07 Million ≈ $45.68 Million |
€-12.81 Million ≈ $-14.97 Million |
-0.328x | -37.19% |
| 2022-12-31 | €55.05 Million ≈ $64.35 Million |
€-13.15 Million ≈ $-15.38 Million |
-0.239x | -2.08% |
| 2021-12-31 | €48.06 Million ≈ $56.18 Million |
€-11.25 Million ≈ $-13.15 Million |
-0.234x | -202.53% |
| 2020-12-31 | €59.06 Million ≈ $69.05 Million |
€-4.57 Million ≈ $-5.34 Million |
-0.077x | -117.28% |
| 2019-12-31 | €-10.19 Million ≈ $-11.91 Million |
€-4.56 Million ≈ $-5.33 Million |
0.448x | -62.78% |
| 2018-12-31 | €-4.46 Million ≈ $-5.22 Million |
€-5.37 Million ≈ $-6.28 Million |
1.203x | +219.08% |
| 2017-12-31 | €-4.29 Million ≈ $-5.01 Million |
€-1.62 Million ≈ $-1.89 Million |
0.377x | -- |
About Hyloris Developmentsen Sa
Hyloris Pharmaceuticals SA engages in the research, development, and manufacture of pharmaceutical products to address medical needs. The company offers Maxigesic IV, a combination of paracetamol and ibuprofen used for post-operative pain, the opioid crisis, and acute pain; Podofilox Gel, an antimycotic drug for the treatment of external genital and perianal warts caused by various types of the h… Read more